Adjuvant Pembrolizumab in Renal Cell Carcinoma: Who Should Receive It?

Authored by Natalia Gandur, published on 2026-05-12 20:56:24.0

This algorithm should answer one focused clinical question: After nephrectomy for high-risk RCC, which patients should receive adjuvant pembrolizumab and which patients should undergo active surveillance?The goal is not to summarize all adjuvant RCC trials. The goal is to help clinicians make a practical post-nephrectomy decision.

Post-nephrectomy or complete resection for renal cell carcinoma (RCC)
- Residual measurable disease?
  
  Restaging with cross-sectional imaging (CT chest/abdomen/pelvis ± brain if indicated)
  - No
    - Histology: clear-cell RCC or clear-cell component?
      
      Review final pathology Include sarcomatoid/rhabdoid features if present
      - No
        
        Pure non–clear cell RCC (papillary, chromophobe, collecting duct, medullary, unclassified, etc.)
        
        → Active surveillance OR clinical trial (preferred)
      - Yes - Clear-cell RCC or clear-cell component
        
        Assess recurrence risk (KEYNOTE-564–style groups)
        
        Risk groups Intermediate–high risk pT2, Grade 4 or sarcomatoid, NO. MO pT3, any grade, NO, MO High risk pT4, any grade, NO, MO Any pT, any grade, N+, MO M1 NED No evidence of disease after complete resection of metastatic sites (within 1 year from nephrectomy) Lower risk (not eligible for adjuvant pembrolizumab) pT1, any grade, NO, MO pT2, Grade 1-2, NO, MO without other high-risk features
        
        Lower risk
        
        Active surveillance (see surveillance panel below)
        
        Active Surveillance Strategy
        
        Imaging: CT chest/abdomen/pelvis (or MRI abdomen/pelvis) q6 months for 3 years, then annually up to 5 years (or as indicated) Labs: CBC, CMP (incl creatinine/eGFR), urinalysis Assess: H&P Symptom review Functional status Educate: Recurrence signs/symptoms Follow-up When to contact care team Re-evaluate: At each visit If recurrence detected → metastatic RCC algorithm
        
        Not high risk. Shared decision making
        
        Discuss potential benefits/risks; patient values & preferences. Potential benefits: Improved disease-free survival (OFS) and overall survival (OS) in high-risk clear-cell RCC (KEYNOTE-664) Reduces risk of recurrence Potential risks: Immune-related adverse events (irAEs) Can be serious and may be permanent Requires regular infusions and monitoring Patient values and preferences: Tolerance for irAEs Willingness to receive treatment vs close surveillance Quality of life considerations
        
        Adjuvant pembrolizumab recommended
        
        Best-fit profile: ccRCC/clear-cell component Intermediate–high risk/high risk/M1 NED Recovered from surgery IO-eligible Acceptable benefit–risk Pembrolizumab 200 mg IV q3w or 400 mg IV q6w for up to 1 year/until recurrence/toxicity/withdrawal.
        
        Borderline / preference-sensitive (shared decision)
        
        Examples: pT3a without other high-risk features Older/significant comorbidities Mild autoimmune history Strongly values recurrence reduction or avoids toxicity. Choice between adjuvant pembrolizumab vs active surveillance based on informed preference.
        
        Active surveillance recommended
        
        Best-fit profile: Low-risk localized RCC Pure non–clear cell RCC IO contraindication/poor recovery High competing mortality risk Preference to avoid toxicity (see active surveillance strategy).
        
        Cycle detected
        
        Node n12 appears again in this branch.
        
        Intermediate–high risk / High risk / M1 NED
        
        Postoperative recovery & timing
        
        Aim to start within 12–16 weeks after nephrectomy (EAU recommendation). Checks: Within 12–16 weeks? Adequate wound healing? ECOG 0–1? Renal function stable? No unresolved postoperative complications?
        
        If not recovered and stable, then delay and reassess
        
        Once recovered: Re-evaluate risk/eligibility Consider within adjuvant window If not feasible → Active surveillance
        
        Yes, recovered and stable
        
        Immunotherapy eligibility - Any contraindication/high-risk condition?
        
        Any contraindication/high-risk condition? Active autoimmune disease Prior severe immune-related toxicity Solid organ transplant Chronic immunosuppression Uncontrolled IBD or severe active inflammatory disease Severe prior pneumonitis or immune hepatitis
        
        Yes, high-risk or contraindication
        
        Immunotherapy not appropriate
        
        → Active surveillance OR clinical trial (if available)
        
        Active Surveillance Strategy
        
        Imaging: CT chest/abdomen/pelvis (or MRI abdomen/pelvis) q6 months for 3 years, then annually up to 5 years (or as indicated) Labs: CBC, CMP (incl creatinine/eGFR), urinalysis Assess: H&P Symptom review Functional status Educate: Recurrence signs/symptoms Follow-up When to contact care team Re-evaluate: At each visit If recurrence detected → metastatic RCC algorithm
        
        Not high risk. Shared decision making
        
        Discuss potential benefits/risks; patient values & preferences. Potential benefits: Improved disease-free survival (OFS) and overall survival (OS) in high-risk clear-cell RCC (KEYNOTE-664) Reduces risk of recurrence Potential risks: Immune-related adverse events (irAEs) Can be serious and may be permanent Requires regular infusions and monitoring Patient values and preferences: Tolerance for irAEs Willingness to receive treatment vs close surveillance Quality of life considerations
        
        Adjuvant pembrolizumab recommended
        
        Best-fit profile: ccRCC/clear-cell component Intermediate–high risk/high risk/M1 NED Recovered from surgery IO-eligible Acceptable benefit–risk Pembrolizumab 200 mg IV q3w or 400 mg IV q6w for up to 1 year/until recurrence/toxicity/withdrawal.
        
        Borderline / preference-sensitive (shared decision)
        
        Examples: pT3a without other high-risk features Older/significant comorbidities Mild autoimmune history Strongly values recurrence reduction or avoids toxicity. Choice between adjuvant pembrolizumab vs active surveillance based on informed preference.
        
        Active surveillance recommended
        
        Best-fit profile: Low-risk localized RCC Pure non–clear cell RCC IO contraindication/poor recovery High competing mortality risk Preference to avoid toxicity (see active surveillance strategy).
        
        Cycle detected
        
        Node n12 appears again in this branch.
        
        Not high risk. Shared decision making
        
        Discuss potential benefits/risks; patient values & preferences. Potential benefits: Improved disease-free survival (OFS) and overall survival (OS) in high-risk clear-cell RCC (KEYNOTE-664) Reduces risk of recurrence Potential risks: Immune-related adverse events (irAEs) Can be serious and may be permanent Requires regular infusions and monitoring Patient values and preferences: Tolerance for irAEs Willingness to receive treatment vs close surveillance Quality of life considerations
        
        Adjuvant pembrolizumab recommended
        
        Best-fit profile: ccRCC/clear-cell component Intermediate–high risk/high risk/M1 NED Recovered from surgery IO-eligible Acceptable benefit–risk Pembrolizumab 200 mg IV q3w or 400 mg IV q6w for up to 1 year/until recurrence/toxicity/withdrawal.
        
        Borderline / preference-sensitive (shared decision)
        
        Examples: pT3a without other high-risk features Older/significant comorbidities Mild autoimmune history Strongly values recurrence reduction or avoids toxicity. Choice between adjuvant pembrolizumab vs active surveillance based on informed preference.
        
        Active surveillance recommended
        
        Best-fit profile: Low-risk localized RCC Pure non–clear cell RCC IO contraindication/poor recovery High competing mortality risk Preference to avoid toxicity (see active surveillance strategy).
        
        Active Surveillance Strategy
        
        Imaging: CT chest/abdomen/pelvis (or MRI abdomen/pelvis) q6 months for 3 years, then annually up to 5 years (or as indicated) Labs: CBC, CMP (incl creatinine/eGFR), urinalysis Assess: H&P Symptom review Functional status Educate: Recurrence signs/symptoms Follow-up When to contact care team Re-evaluate: At each visit If recurrence detected → metastatic RCC algorithm
        
        Cycle detected
        
        Node n11 appears again in this branch.
  - Yes
    
    If residual or unresected metastatic disease use metastatic RCC treatment algorithm.
Key principles

Adjuvant pembrolizumab improves DFS and OS in high-risk clear-cell RCC (KEYNOTE-564) Benefit must be balanced against irA risk in potentially cured patients Active surveillance is an evidence-supported, patient-centered option Clinical trials should be considered when eligibility or evidence is uncertain

tos privacy Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial NCCN Kidney Cancer guidelines Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up EAU Guidelines on Renal Cell Carcinoma